J&J is forced to sus­pend re­cruit­ment in PhI di­a­betes study, rais­ing ques­tions about an­oth­er Han­mi drug

J&J has run in­to a prob­lem with a Phase I di­a­betes drug — JNJ-64565111 — in-li­censed from South Ko­rea’s Han­mi. The in­ves­ti­ga­tors on the study re­port­ed on clin­i­cal­tri­als.gov that the tri­al has sus­pend­ed pa­tient re­cruit­ment, and a spokesper­son for J&J tells me that the de­lay was due to “a man­u­fac­tur­ing-re­lat­ed de­lay.”

“Our part­ner­ship with Han­mi re­mains strong re­gard­ing this drug can­di­date and we look for­ward to restart­ing the study,” she added.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.